- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01217788
Intranasal PH94B for Management of the Symptoms of Generalized Social Phobia (PH94B-SAD)
Double Blind Placebo Controlled Study of PH94B for Management of the Symptoms of Generalized Social Phobia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The essential features of generalized social phobia are defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), criteria as a marked and persistent fear of most (generally accepted as four or more) social or performance situations in which the patient believes embarrassment could occur as a consequence of exposure to unfamiliar people and/or possible scrutiny by others. The anxiety resulting from the social or performance situation is profound. The avoidance, fear, or anxious anticipation of these situations interferes significantly with the person's daily routine, having a marked impact on occupational functioning and/or social life. The disorder has a lifetime prevalence estimated at up to 13%, with onset typically in the mid-teens, and it is diagnosed slightly more frequently in females than in males. Social phobia tends to be a chronic disorder with periods of exacerbation, with a reported mean duration of illness of approximately 20 years.
There are two subtypes of social phobia: (i) generalized (discrete), which is suffered by approximately 50% of social phobia patients and in which fear and avoidance extend to a wide range of social situations, and (ii) non-generalized, in which the patient fears only one or a few circumscribed situations. Speaking in front of large groups is by far the most prevalent of social fears (Lang and Stein, 2001).
Social phobia has a lifetime comorbidity rate of approximately 81% with other psychiatric disorders (particularly affective disorders, other anxiety disorders, and substance abuse disorders), as well as to being associated with increased nonpsychiatric medical difficulties. People with social phobia identify social impairment, inadequate social support, overall role impairment, specific impairment in education, work, and other activities, as well as interference in their efforts at self-improvement. Unfortunately, for these patients, there is a strong consensus that social phobia is one of the least commonly recognized and treated mental disorders
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New York
-
New York City, New York, United States, 10024
- Medical Research Network
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject currently meets the Diagnosis of Social Phobia as defined in Diagnostic and Statistical Manual of Mental Disorders, 4th Edition which is not secondary to another pre-existing psychiatric condition or to a medical condition.
- Liebowitz Social Anxiety Scale (LSAS) score greater than or equal to 60 at Screening.
- Score of 75 or greater on the SUD scale at one of the Performance Phase time points during either the Public Speaking or Social Interaction Challenge
- Written Informed Consent prior to commencing any study specific procedures.
- Women of child-bearing-potential must be able to commit to the consistent and correct use of an acceptable method of birth control throughout the study and have a negative serum pregnancy test result prior to study drug administration.
Exclusion Criteria:
- Use of any psychotropic medication within 30 days prior to study entry.
- Acute or chronic psychiatric disease which is the primary diagnosis (except Social Phobia) at the time of the study. Note that subjects with concurrent Generalized Anxiety Disorder (GAD) are allowed into the study provided this is not the primary diagnosis.
- Subjects with a history of psychiatric diseases such as schizophrenia, bipolar disorder, and psychosis are to be excluded.
- Presence of a clinical condition or disease, or use of a concomitant medication, that in the clinical judgment of the Investigator could place the patient at undue risk, interfere with study participation, or confound the results of the study.
- Use of substances of abuse within the year prior to study entry.
- Concomitant use of any over-the-counter, prescription product, or herbal preparation for treatment of the symptoms of social anxiety during the study and within 30 days prior to study entry and use of non-study anxiolytics such as benzodiazepines during the study and within 30 days prior to study entry.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PH94B intranasal spray
|
Comparison of PH94B single dose intranasal spray and Placebo single dose intranasal spray
|
Placebo Comparator: Placebo intranasal spray
|
Comparison of PH94B single dose intranasal spray and Placebo single dose intranasal spray
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Subjective Unit of Discomfort Scale
Time Frame: Once before and again 10 minutes after intranasal dosing with PH94B spray, during exposure to a public speaking challenge
|
Once before and again 10 minutes after intranasal dosing with PH94B spray, during exposure to a public speaking challenge
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients with adverse events as a measure of safety and tolerability on the psychometric scale
Time Frame: Once at the end of the intervention and again one week after intervention (follow-up)
|
One time after dosing and up to one week after dosing.
|
Once at the end of the intervention and again one week after intervention (follow-up)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Michael L Liebowitz, M.D., Medical Research Network
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PH94B CL022
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Social Anxiety Disorder
-
Aya Technologies LimitedCompletedSocial Anxiety | Social Anxiety Disorder | Social Anxiety Disorder (Social Phobia)United Kingdom
-
Tel Aviv UniversityCompletedSocial Anxiety | Social Anxiety Disorder | Social Anxiety Disorder (Social Phobia)Israel
-
University of BernUniversity of LuebeckActive, not recruitingSocial Anxiety Disorder (Social Phobia)Switzerland
-
Aya Technologies LimitedCompletedSocial Anxiety | Social Anxiety Disorder | Social Anxiety Disorder (Social Phobia)United Kingdom
-
Daniel LiebermanTerminatedAnxiety | Anxiety Disorder SocialUnited States
-
Weill Medical College of Cornell UniversityBrain & Behavior Research FoundationTerminatedSocial Anxiety | Social Anxiety Disorder | Social Anxiety Disorder of ChildhoodUnited States
-
Tufts UniversityCompletedSocial Anxiety | Social Anxiety Disorder | Social Anxiety Disorder of ChildhoodUnited States
-
Sumitomo Pharma America, Inc.BehaVR LLCCompletedSocial Anxiety Disorder (SAD)United States
-
Emory UniversityBristol-Myers SquibbCompleted
-
Florida International UniversityYale UniversityRecruitingSocial Anxiety Disorder of ChildhoodUnited States
Clinical Trials on PH94B intranasal spray
-
VistaGen Therapeutics, Inc.TerminatedSocial Anxiety DisorderUnited States
-
VistaGen Therapeutics, Inc.CompletedSocial Anxiety DisorderUnited States
-
Pherin Pharmaceuticals, Inc.UnknownPremenstrual Dysphoric DisorderUnited States
-
Massachusetts General HospitalUnited States Department of DefenseRecruitingAutism Spectrum Disorder | Bone HealthUnited States
-
University of FloridaNational Institute on Aging (NIA)Terminated
-
VistaGen Therapeutics, Inc.TerminatedSocial Anxiety DisorderUnited States
-
George Washington UniversityCompletedSleep Apnea, ObstructiveUnited States
-
University of North Carolina, Chapel HillCompletedAlcohol Dependence | Alcohol Withdrawal
-
VistaGen Therapeutics, Inc.CompletedAdjustment Disorder With Anxious MoodUnited States